Hugh Young

Hugh Young

Company: Imago BioSciences

Job title: Reinhoff, CEO


Hugh Young Rienhoff, Jr., M.D., is a San Francisco Bay area physician and entrepreneur.  He is the Founder and CEO of Imago BioSciences, his fourth start-up. Previously Hugh founded and was CEO of FerroKin BioSciences until it was acquired by Shire plc in 2012. Hugh spent several years as a venture capitalist and was the first dedicated biotech investing partner at NEA beginning in 1992.  Hugh has served on numerous boards including as a founding director of Healtheon/WebMD, Wilson Therapeutics, and Aurora Biosciences.  Hugh obtained his Bachelor of Arts degree from Williams College, studied mathematics at Harvard University, and received the Doctor of Medicine degree from the Johns Hopkins University School of Medicine.


Panel: The Role of Epigenetics in an Oncology Portfolio 5:40 pm

Utilizing epigenetics in combination with immunotherapies to further bolster the immune response Building a differentiated oncology portfolio based on standalone epigenetic (mono)therapies Imagining the future of epigenetic therapies in oncology and beyondRead more

day: Virtual Conference Day

The antileukemic effect exerted by LSD1 inhibition 5:20 pm

Read more

day: Virtual Conference Day

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.